.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Healthtrust
Citi
Covington
Boehringer Ingelheim
Fish and Richardson
Merck
Cantor Fitzgerald
Daiichi Sankyo
Harvard Business School

Generated: December 18, 2017

DrugPatentWatch Database Preview

Candesartan cilexetil; hydrochlorothiazide - Generic Drug Details

« Back to Dashboard

What are the generic sources for candesartan cilexetil; hydrochlorothiazide and what is the scope of candesartan cilexetil; hydrochlorothiazide patent protection?

Candesartan cilexetil; hydrochlorothiazide
is the generic ingredient in two branded drugs marketed by Astrazeneca, Apotex Inc, Dr Reddys Labs Ltd, Macleods Pharms Ltd, and Mylan Pharms Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for candesartan cilexetil; hydrochlorothiazide. Six suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for candesartan cilexetil; hydrochlorothiazide

Pharmacology for candesartan cilexetil; hydrochlorothiazide

Tentative approvals for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Applicant Application No. Strength Dosage Form
u► Subscribe16MG; 12.5MGTABLET; ORAL
u► Subscribe32MG; 25MGTABLET; ORAL
u► Subscribe32MG; 12.5MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Macleods Pharms LtdCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL204100-001Feb 27, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-003May 16, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe
Apotex IncCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL202884-001Dec 4, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms IncCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL090704-003Dec 4, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Macleods Pharms LtdCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL204100-002Feb 27, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Macleods Pharms LtdCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL204100-003Feb 27, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs LtdCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL202965-003Jun 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex IncCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL202884-003Jun 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-002Sep 5, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs LtdCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDEcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL202965-001Jun 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: candesartan cilexetil; hydrochlorothiazide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-002Sep 5, 2000► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-003May 16, 2008► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-002Sep 5, 2000► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-001Sep 5, 2000► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-002Sep 5, 2000► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-001Sep 5, 2000► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-003May 16, 2008► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-003May 16, 2008► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-003May 16, 2008► Subscribe► Subscribe
AstrazenecaATACAND HCTcandesartan cilexetil; hydrochlorothiazideTABLET;ORAL021093-003May 16, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Merck
Dow
McKinsey
Argus Health
Accenture
Covington
Medtronic
Novartis
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot